Eisai posts first U.S. sales numbers for Alzheimer's drug; FDA grants priority review for Sage depression drug

Taking stock of the drug industry, from the lab to the medicine chest

February 6, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Eisai reports first U.S. sales of newly approved treatment for Alzheimer's disease The first U.S. sales of Leqembi were recorded on Jan. 18, Eisai said during its presentation of financial results. By Adam Feuerstein STAT+ | FDA grants priority review for Sage's rapid-acting treatment for depression The agency has not indicated yet whether it will convene an advisory panel of outside experts to review the zuranolone clinical data. By Adam Feuerstein Opinion: FDA: Base blood donation policy on science, not stigma The FDA should make permanent its plan to include gay men in blood donation programs without stigmatizing restrictions. By Scott Jelinek Pat Greenhouse/Boston Globe STAT+ | Boston biotech internship program aims to increase diversity through expansion Project Onramp launched in 2019 by the Boston nonprofit Life Science Cares to infuse diversity into the region's largely white biotech sector. By Ryan Cross — The Boston Globe

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

REPORTS NEWSLETTERS EVENTS STAT+

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser